Premium
Plasma thrombopoietin level and platelet indices in hemodialysis patients receiving recombinant human erythropoietin
Author(s) -
ASANUMA M.,
SEINO K.,
MIZUNO T.,
NASU M.,
YAMAUCHI F.,
FUJISHIMA M.
Publication year - 2010
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2009.01191.x
Subject(s) - thrombopoietin , erythropoietin , platelet , hemodialysis , recombinant dna , medicine , immunology , pharmacology , chemistry , biology , haematopoiesis , biochemistry , genetics , stem cell , gene
Summary We focused on thrombocytopenia in hemodialysis patients (HD) receiving recombinant human erythropoietin (rHuEPO) and investigated thrombopoietin (TPO) level and platelet indices. We analyzed platelet parameters including mean platelet volume (MPV), platelet‐crit (PCT), mean platelet component (MPC) concentration and platelet count (PLT) using ADVIA 2120 in 375 HD patients. This study included 25 HD patients undergoing treatment with rHuEPO at 9000 IU/week. These patients were divided into two groups by reference PLT of 130 × 10 9 /l [eight patients with low PLT (L‐PLT group) and 17 patients with normal PLT (N‐PLT group)], and TPO level and platelet indices in each group were compared with those in nine HD patients not receiving rHuEPO. In HD patients, the mean value of MPV was slightly higher and the mean values of PLT, PCT, and MPC were significantly lower than those in healthy controls. TPO levels were significantly higher in patients receiving rHuEPO than in patients not receiving rHuEPO. However, no significant difference was found between TPO levels in patients in the L‐PLT group and patients in the N‐PLT group. TPO levels were not correlated with PLT in these patients and that MPC levels decreased remarkably regardless of PLT.